10-K: AdaptHealth Reports 2025 Net Loss Amid Revenue Dip & Impairment

AdaptHealth Corp. reported a net loss of $70.8 million for the fiscal year ended December 31, 2025, driven by a goodwill impairment charge and a slight revenue decrease.

Summary

• Net revenue for the year ended December 31, 2025, decreased by 0.5% to $3.24 billion, compared to $3.26 billion in the prior year.
• The company recorded a net loss attributable to AdaptHealth Corp. of $70.8 million in 2025, a significant decline from a net income of $90.4 million in 2024.
• Operating income decreased by 65.5% to $90.9 million in 2025 from $263.7 million in 2024.
• A non-cash goodwill impairment charge of $128.0 million was recognized in 2025, primarily related to the Diabetes Health reporting unit.
• Adjusted EBITDA decreased by 10.4% to $616.7 million in 2025, with the Adjusted EBITDA Margin falling to 19.0% from 21.1% in 2024.
• Free cash flow decreased by 7.0% to $219.4 million in 2025, compared to $235.8 million in 2024.
• Working capital saw a substantial decrease, from $188.8 million in 2024 to $16.5 million in 2025.
• The Sleep Health segment's net revenue increased by 2.1% to $1.38 billion, driven by higher patient census for PAP resupply products.
• The Respiratory Health segment's net revenue increased by 6.1% to $691.2 million, due to higher fixed monthly equipment reimbursements from increased oxygen equipment patient census.
• The Diabetes Health segment's net revenue decreased by 3.6% to $592.4 million, primarily due to a shift in payor mix from commercial insurance to government payors.
• The Wellness at Home segment's net revenue decreased by 9.8% to $583.1 million, largely due to the disposition of certain incontinence and infusion businesses, which reduced net revenue by $92.4 million.
• The company completed the disposition of certain incontinence and infusion businesses in 2025, generating pre-tax gains of $32.6 million.
• AdaptHealth is involved in several legal proceedings, including a proposed $35.0 million securities class action settlement ($1.0 million funded by the company) and a proposed $14.5 million settlement for a North Carolina debt collection class action.
• Two civil investigative demands were issued by the U.S. Attorney's Office under the False Claims Act regarding billing practices for humidifiers (South Carolina, July 2024) and respiratory devices (Eastern District of Pennsylvania, March 2025).

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative filing due to the reported net loss, significant goodwill impairment, and declines in operating income and Adjusted EBITDA, despite some organic revenue growth. Multiple ongoing legal and regulatory challenges add to the uncertainty.

Positives

• Organic revenue increased by $56.9 million, or 1.7%, demonstrating growth within existing operations.
• Sleep Health segment revenue grew by 2.1% due to higher patient census for PAP resupply products.
• Respiratory Health segment revenue increased by 6.1% due to higher patient census for oxygen equipment products.
• Interest expense, net, decreased by $20.9 million (16.5%) in 2025, attributed to lower average outstanding borrowings and lower interest rates.
• The company recognized a pre-tax gain of $32.6 million from the disposition of certain incontinence and infusion businesses, aligning with strategic priorities.
• Internal control over financial reporting was deemed effective as of December 31, 2025, remediating a previously reported material weakness in inventory valuation.

Negatives

• The company reported a net loss of $70.8 million in 2025, a significant reversal from a net income of $90.4 million in 2024.
• Total net revenue decreased by 0.5% year-over-year, primarily due to dispositions offsetting organic growth.
• Operating income declined sharply by 65.5% to $90.9 million.
• A substantial non-cash goodwill impairment charge of $128.0 million was recognized for the Diabetes Health reporting unit.
• Adjusted EBITDA decreased by 10.4% and Adjusted EBITDA Margin declined to 19.0%.
• Working capital significantly decreased from $188.8 million in 2024 to $16.5 million in 2025.
• The Diabetes Health segment experienced a 3.6% revenue decrease due to an unfavorable shift in payor mix from commercial to government payors.
• The Wellness at Home segment's revenue decreased by 9.8%, largely due to dispositions.
• The company is facing multiple legal proceedings, including a securities class action settlement and a debt collection class action settlement, requiring cash payments.
• Two ongoing False Claims Act investigations by the U.S. Attorney's Office pose potential material adverse effects.

Risks

• Reliance on a few suppliers for patient service equipment and supplies, leading to vulnerability to price increases or supply chain disruptions.
• Economy-wide labor shortages and increased labor costs, potentially exacerbated by union activity.
• Negative impact of inflation and rising interest rates on costs, demand, margins, and debt refinancing.
• Dependence on information systems and third-party software, with risks of failure, disruption, cyber-attacks, or data breaches.
• Adverse impact if expenses under capitated agreements exceed revenues.
• Continuing efforts by private third-party payors to control costs, leading to potential lower reimbursement rates or contract renegotiations/terminations.
• Changes in governmental or private payor supply replenishment schedules could adversely affect revenue.
• Challenges in managing the complex and lengthy reimbursement process, potentially leading to delays or uncollectible payments.
• High dependence on sleep therapy equipment and supplies (42.5% of net revenue in 2025), making the business vulnerable to changes in this market.
• Adverse effects from consolidation among health insurers and other industry participants.
• Inability to maintain or develop relationships with patient referral sources.
• Intense competition from national, regional, and product-specific providers, as well as new entrants like CVS and Amazon.
• Changes in medical equipment technology and development of new treatments (e.g., GLP-1 drugs for obesity/diabetes) could render current offerings obsolete.
• Risks associated with the use or anticipated use of artificial intelligence (AI) technologies, including reputational harm, competitive harm, and legal liability.
• Inherent risks in transporting compressed and liquid oxygen, including rupture or accidents.
• Risks associated with outsourcing internal business functions to third-party providers in India and the Philippines, including political unrest, public health crises, and cyber-attacks.
• Loss of key personnel, including senior management, could negatively impact operations.
• Challenges in executing strategic growth plans, particularly integrating acquired companies and realizing expected benefits.
• Adverse effects from political and economic conditions, including international conflicts, government shutdowns, and tariffs.
• Potential for losses not covered by insurance or claims exceeding estimates, particularly with self-insurance programs.
• Impact of federal and state changes to reimbursement and other Medicaid and Medicare policies, including the OBBBA and CBP.
• Increased audit activity and enforcement efforts by governmental and private payor entities, potentially leading to payment denials or recoupments.
• Failure to maintain required licenses and accreditation could impact operations.
• Non-compliance with data protection, privacy, security, and consumer protection laws (HIPAA, HITECH Act, CCPA, TCPA).
• Adverse effects from global climate change or legal/regulatory responses to such change, including disclosure mandates and compliance costs.
• Requirement to write down all or part of goodwill, materially affecting net earnings and net worth (already incurred $128.0 million in 2025).
• Inability to generate sufficient cash flow to cover required payments or comply with financial and operating covenants under long-term debt and leases.
• Need for additional capital to fund operating subsidiaries and growth, with uncertainty of obtaining it on acceptable terms.
• Dependence on distributions from AdaptHealth Holdings to meet financial obligations.
• Significant and potentially exceeding actual benefits payments required under the Tax Receivable Agreement (TRA).
• Fluctuations in the price of AdaptHealth's securities.
• Significant influence of principal stockholders (OEP AHCO Investment Holdings, LLC and Deerfield Management Company, L.P.) over corporate actions.
• No current plans to pay cash dividends on Common Stock.
• Exclusive forum provisions in the Charter may discourage lawsuits against directors and officers.

Future Outlook

The company anticipates continued regulatory changes, with the One Big Beautiful Bill Act (OBBBA) provisions affecting Medicaid eligibility and enrollment taking effect in 2027 or later. The DMEPOS Competitive Bidding Program is set to resume in 2026, with contracts effective no later than January 1, 2028, which could alter reimbursement rates. New or expanded climate-related laws, such as California's SB-253 and SB-261, are expected to impose compliance costs, with regulations anticipated in 2026. The long-term impact of new treatments like GLP-1 drugs for obesity and type 2 diabetes on demand for current equipment and services remains uncertain. The company expects its operating cash flows, existing cash, and credit agreement to be sufficient for operations and growth strategies for at least the next twelve months, but may seek additional equity or debt financing for acquisitions.

Management Comments

• Management believes its expected operating cash flows, together with existing cash and amounts available under its existing credit agreement, will continue to be sufficient to fund its operations and growth strategies for at least the next twelve months.
• Management believes that relations between its management and employees are good, and it is committed to inclusion and policies and procedures to maintain a safe work environment.
• Management believes that its facilities are adequate to meet its current needs and reviews its facility footprint regularly to add locations as needed to support patient growth.
• Management believes that its relationships with its referral sources are strong and that these entities will continue to be a source of organic revenue through new patients.
• Management believes it is in material compliance with all statutes and regulations applicable to its operations.
• Management believes any liability that may ultimately result from resolution of current loss contingencies will not have a material adverse effect on the company's financial condition or results of operations, though this assessment may change.

Industry Context

StockSavvy.ai notes that the home medical equipment (HME) market remains highly fragmented and competitive, with ongoing consolidation trends favoring larger providers with integrated technology. The industry faces significant regulatory pressures, including changes to Medicare and Medicaid reimbursement policies, such as the resumption of the Competitive Bidding Program and the impacts of the OBBBA. The increasing scrutiny on billing practices, as evidenced by the False Claims Act investigations, highlights the heightened compliance risks. The emergence of new medical technologies and treatments, like GLP-1 drugs, presents both opportunities and threats, potentially shifting demand for traditional HME products. The entry of large technology companies and pharmacy benefit managers into the HME space signals an evolving competitive landscape.

Comparison to Industry Standards

• The HME market is highly competitive, with AdaptHealth competing against large national providers like Accendra Health, Lincare Holdings Inc., Rotech Healthcare, Inc., Cardinal Health, Inc., and Quipt Home Medical Corp. The filing does not provide specific comparative financial metrics or project results for these competitors to benchmark AdaptHealth's performance directly against them.
• The company's reliance on a few key suppliers is a common industry characteristic, but the filing highlights it as a risk, suggesting potential vulnerability compared to more diversified supply chains.
• The industry-wide labor shortages and inflationary pressures mentioned are consistent with broader macroeconomic trends affecting many healthcare and logistics-dependent sectors.
• The ongoing regulatory changes, such as the DMEPOS Competitive Bidding Program and the OBBBA, are industry-wide challenges that all HME providers must navigate, and AdaptHealth's performance will be influenced by its ability to adapt to these shifts relative to its peers.

Corporate Governance

Legal Proceedings

• Allegheny County Consolidated Class Action: Proposed settlement of $35.0 million ($34.0 million from insurers, $1.0 million from company) for alleged federal securities law violations related to billing practices and compliance programs. Preliminary court approval granted February 2, 2026.
• Wu Derivative Action: Shareholder derivative complaint alleging breach of fiduciary duties and federal securities law violations, stayed pending resolution of the Allegheny County Consolidated Class Action.
• Frankel Derivative Action: Shareholder derivative complaint filed December 9, 2025, alleging breach of fiduciary duties and federal securities law violations, related to the Allegheny County allegations.
• Myers Derivative Action: Shareholder derivative complaint filed February 6, 2026, alleging breach of fiduciary duty, insider trading, and unjust enrichment under Delaware law, related to the Allegheny County allegations.
• North Carolina Debt Collection Practices Act Class Action: Proposed settlement of $14.5 million by the company for alleged improper billing and late fees for approximately 130,000 North Carolina patients. Outcome is contingent on court approval.
• U.S. Attorney's Office (South Carolina) Civil Investigative Demand: Issued July 29, 2024, under the False Claims Act, investigating billing and reimbursements for humidifiers integrated with PAP devices from January 1, 2017, to present.
• U.S. Attorney's Office (Eastern District of Pennsylvania) Civil Investigative Demand: Issued March 8, 2025, under the False Claims Act, investigating billing and reimbursements for respiratory devices and related supplies from January 1, 2018, to present.

Related Party Transactions

• The company incurred $19.1 million in expenses from a vendor providing automated order intake software, in which AdaptHealth holds an equity interest.
• Net revenue of approximately 1.1% of consolidated net revenue was derived from a third-party payor whose board of directors includes a director of AdaptHealth.
• Payments of approximately $77.7 million were made to a medical equipment and supplies vendor, where a director of AdaptHealth is an employee of a beneficial owner (over 5% Common Stock) and minority shareholder of the vendor.

Stakeholder Impact

• Shareholders: Experienced a net loss and goodwill impairment, potentially impacting stock value. The proposed securities class action settlement aims to resolve claims from shareholders who purchased stock between August 4, 2020, and November 7, 2023.
• Patients: Continued to receive patient-centered, healthcare-at-home solutions, with approximately 4.3 million patients serviced annually. However, changes in payor policies and competitive bidding programs could affect access and costs.
• Employees: The company had approximately 10,900 employees as of December 31, 2025. Labor shortages and increased labor costs are noted risks, potentially impacting employee compensation and workload. Equity-based compensation is used to attract and retain talent.
• Payors (Medicare, Medicaid, Commercial Insurers): Subject to ongoing audits and regulatory changes, including the OBBBA and CBP, which could affect reimbursement rates and administrative processes. The company derived 26% of its net revenue from government healthcare programs.
• Suppliers: The company's reliance on a few key suppliers creates a dependency that could be impacted by supply chain disruptions or price increases, potentially affecting product availability and costs.

Next Steps

• Negotiate and finalize the formal settlement agreement for the Allegheny County Consolidated Class Action and seek final court approval.
• Continue to vigorously defend against the Wu Derivative Action, Frankel Derivative Action, and Myers Derivative Action.
• Finalize additional material terms and seek preliminary and final court approvals for the North Carolina Debt Collection Practices Act class action settlement.
• Cooperate fully with the U.S. Attorney's Office investigations under the False Claims Act.
• Monitor developments regarding the SEC's climate disclosure rule and California's climate-related laws, with CARB regulations expected in 2026.
• Adapt to the resumption of the DMEPOS Competitive Bidding Program, with the bid window opening in late summer/early fall 2026 and contracts effective no later than January 1, 2028.
• Adjust operations and processes to ensure compliance with Medicare and Medicaid regulations as COVID-19 waivers and flexibilities terminate.
• Continue to evaluate changes in medical equipment technology and new treatments, such as GLP-1 drugs, to adapt product offerings.
• Manage the 2024 Term Loan, with quarterly principal repayments of $4.1 million through September 30, 2026, increasing to $8.1 million thereafter.
• Address the potential maturity acceleration of the 2024 Credit Facility if the 6.125% Senior Notes are not refinanced or repaid by December 31, 2027, and the 4.625% Senior Notes by December 31, 2028.
• Continue to implement and optimize AI programs to improve patient and operational workflows.
• Monitor and adapt to the implementation of the One Big Beautiful Bill Act (OBBBA) provisions, particularly those affecting Medicaid funding and enrollment starting in 2027.

Key Dates

Recommendation

The company reported a net loss and significant goodwill impairment, indicating financial challenges. While there's organic revenue growth in some segments and strategic dispositions, the overall financial performance is weak. Multiple ongoing legal and regulatory investigations create substantial uncertainty and potential future liabilities. The stock price has been volatile, reflecting these risks. For existing investors, holding might be a strategy to await potential improvements from strategic initiatives and resolution of legal matters, but new investment carries high risk given the current financial and operational headwinds.

Keywords

Home Medical Equipment, HME, Sleep Therapy, Respiratory Health, Diabetes Health, Wellness at Home, SEC Filing, 10-K, Financial Results, Goodwill Impairment, Net Loss, Adjusted EBITDA, Revenue, Healthcare, Medical Supplies, CPAP, Oxygen Therapy, Continuous Glucose Monitors, Insulin Pumps, Acquisitions, Dispositions, Legal Proceedings, False Claims Act, SEC, Medicare, Medicaid, OBBBA, Competitive Bidding Program, Cybersecurity, Risk Factors